Venenum Biodesign

A Member of Genesis Biotechnology Group

Careers Page


Please view our career page for future employment with Venenum Biodesign.

View Job Postings

Venenum’s Compound Collection and Technology


VENENUM Biodesign‘s Collection of small molecule compounds contains large diverse discovery libraries (ECLiPS libraries) as well as targeted libraries (VTLs). Both types of libraries are designed by experienced medicinal and computational chemists to maximize the probability for lead compound generation. Our ECLiPS collection is comprised of 6 million small molecules with drug-like properties. It is a proven deck for HTS with a success rate of ~ 70% across pharmaceutical targets including GPCRs, enzymes, NHRs, transporters and ion channels. New target challenges in protein – protein interactions (PPI) and protein – DNA interactions (PDI) require new chemistry libraries. While PPI and PDI are at the core of many essential biological processes, such as transcription or cytokine signaling, the discovery of small molecule inhibitors of these interactions has been historically challenging. VENENUM Biodesign‘s chemists and molecular modelers are currently designing and synthesizing a series of new libraries aimed at these challenging targets. Both VTLs (sets of 500-700 compounds) and larger (20,000- 30,000 compounds) ECLiPS libraries are being synthesized based on in-house design ideas.

The ECLiPS technology, licensed from Columbia University, is an integrated solid-phase synthesis and screening technology implemented by Pharmacopeia in the mid-1990’s. ECLiPS was used successfully by Pharmacopeia for 12 years to identify hits, drive lead optimization, and nominate Development Candidates (DC) in collaborations with pharmaceutical and biotech companies. Ligand Pharmaceuticals acquired Pharmacopeia in 2008, and VENENUM Biodesign acquired the ECLiPS technology from Ligand Pharmaceuticals in 2010. VENENUM Biodesign has used ECLiPS to develop its own drug discovery pipeline. VENENUM Biodesign‘s business model is to partner its programs at or near DC, thus allowing VENENUM Biodesign to concentrate on the discovery of new targets and new chemical entities.